Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 with Pembrolizumab and Nab-Paclitaxel in Metastatic TNBC
NCT05422794Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZEN3694 in triple-negative breast cancer (TNBC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 28 days, Recommended Phase 2 Dose up to 28 days and 1 more. Started May 2023; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05422794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422794.